Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

BACKGROUND Remdesivir improves clinical outcomes in patients hospitalized with moderate-to-severe coronavirus disease 2019 (Covid-19). Whether the use of remdesivir in symptomatic, nonhospitalized patients with Covid-19 who are at high risk for disease progression prevents hospitalization is uncerta...

Full description

Bibliographic Details
Main Authors: Abdelghany, M. (Author), Behenna-Renton, N. (Author), Brown, M. (Author), Brown, S.M (Author), Camus, G. (Author), Chen, S. (Author), Davies, S. (Author), Duff, F. (Author), Ginde, A.A (Author), Gottlieb, R.L (Author), Hidalgo, A. (Author), Hill, J.A (Author), Hyland, R.H (Author), Juneja, K. (Author), Katz, M.J (Author), Marty, F.M (Author), Mera, J. (Author), Mittal, S. (Author), Nielsen, B.U (Author), Oguchi, G. (Author), Osinusi, A. (Author), Osiyemi, O. (Author), Paredes, R. (Author), Perez, G. (Author), Ryan, P. (Author), Sachdeva, Y. (Author), Schiffer, J.T (Author), Skarbinski, J. (Author), Vaca, C.E (Author), Webb, B.J (Author)
Format: Article
Language:English
Published: Massachussetts Medical Society 2022
Subjects:
Adenosine Monophosphate
adenosine phosphate
adult
Adult
aged
Aged
Aged, 80 and over
ageusia
alanine
Alanine
anosmia
Antiviral Agents
antivirus agent
Article
chill
clinical trial
comorbidity
Comorbidity
complication
controlled study
coronavirus disease 2019
coughing
COVID-19
diabetes mellitus
diarrhea
disease course
disease exacerbation
Disease Progression
disease severity
dizziness
double blind procedure
Double-Blind Method
drug dose regimen
drug effect
drug efficacy
drug safety
drug therapy
dyspnea
fatigue
female
Female
fever
headache
high risk patient
Hispanic
hospitalization
Hospitalization
human
Humans
hypertension
major clinical study
male
Male
middle aged
Middle Aged
mortality
mortality rate
multicenter study
nausea
obesity
outpatient
outpatient care
Outpatients
placebo
randomized controlled trial
remdesivir
risk factor
SARS-CoV-2
time to treatment
Time-to-Treatment
treatment duration
very elderly
Viral Load
virus load
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items